1. How many patients over the last 4 months (January to April 2022) have received the following anti-VEGF treatments for any eye condition:
a. Aflibercept
b. Bevacizumab
c. Brolucizumab
d. Dexamethasone
e. Ranibizumab
2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.
a. Aflibercept
b. Bevacizumab
c. Brolucizumab
d. Dexamethasone
e. Ranibizumab
3. Please provide the number of patients treated for Diabetic Macular Oedema (DMO) ONLY in the last 4 months (January to April 2022) with the following:
a. Aflibercept
b. Bevacizumab
c. Dexamethasone
d. Ranibizumab
4. Please provide the number of patients treated for Retinal Vein Occlusion (RVO) ONLY in the last 4 months (January to April 2022) with the following:
a. Aflibercept
b. Bevacizumab
c. Dexamethasone
d. Ranibizumab

High-cost intra-vitreal treatments in Ophthalmology.030622.docx